HLA-B*1502 gene detection analysis and medication risk assessment in patients with bipolar disorder
Objective To detect and analyze the polymorphism of human leukocyte antigen-B*1502(HLA-B*1502)gene in patients with bipolar disorder(BD),and to evaluate the risk of skin adverse reactions induced by Lamotrigine.Methods A total of 510 patients who were treated in Zaozhuang Maternal and Child Health Hospital from January 2019 to August 2022 and detected HLA-B*1502 genotype and medication guidance by fluorescence staining in situ hybridization sequencing be-fore the initial use of Lamotrigine were retrospectively collected as research objects.The genotype and the occurrence of skin type adverse drug reactions were analyzed.Results The proportion of positive HLA-B*1502 gene was lower than that of neg-ative HLA-B*1502 gene,and the difference was statistically significant(P＜0.05).Among HLA-B*1502 gene positive re-sults,the proportion of heterozygous mutants was higher than that of homozygous mutants,and the difference was statistically significant(P＜0.01).Conclusion Clinical during the initial use of Lamotrigine to control and treat patients with BD,HLA-B*1502 gene testing is necessary to reduce the risk of skin adverse reactions induced by Lamotrigine.
Bipolar disorderLamotrigineSkin adverse drug reactionsHLA-B*1502
万方数据
